New Gastro Guidelines; Best First-Line Option in UC? Late-Stage Trial Win for Hep D

The American Gastroenterological Association (AGA) published guideline updates on managing metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease and surveillance for pancreatic cystic lesions and hepatocellular carcinoma (HCC) in older adults. (Clinical Gastroenterology and Hepatology)

European societies published guidelines on resmetirom (Rezdiffra) or semaglutide (Wegovy) for metabolic dysfunction-associated steatohepatitis, and U.S. societies including the AGA offered consensus recommendations on diagnosing and managing serrated polyposis syndrome. (Journal of Hepatology, Gastroenterology)

A phase II trial produced promising safety and efficacy data for investigational tipelukast as a treatment for hypertriglyceridemia and MASLD associated with type 2 diabetes, MediciNova announced.

Experts writing in Lancet Gastroenterology & Hepatology reviewed the management of pain in chronic pancreatitis with a focus on non-opioid options.

Yet another study found that very preterm infants who received probiotic supplementation had a lower risk for necrotizing enterocolitis. (JAMA Network Open)

A 5-year analysis showed that ulcerative colitis (UC) patients starting vedolizumab (Entyvio) as first-line treatment spent more time with corticosteroid-free disease compared with those starting on a TNF inhibitor. (JAMA Network Open)

Meanwhile, in TNF-exposed patients with UC, retrospective data favored upadacitinib (Rinvoq) for effectiveness over vedolizumab but at a price of more adverse events. (Inflammatory Bowel Diseases)

Development of Crohn’s disease following a negative small bowel video capsule endoscopy was reassuringly uncommon in an Israeli cohort study with over a decade of median follow-up. (Inflammatory Bowel Diseases)

While recommended in guidelines, exactly how effective is medical-behavioral therapy for fecal incontinence? (Clinical Gastroenterology and Hepatology)

Researchers in Gut linked certain microbiome profiles in patients with cirrhosis to increased hospitalization risk.

The phase III portion of AZURE-1 testing investigational brelovitug in chronic hepatitis delta virus met its primary endpoint of virologic response and alanine aminotransferase normalization, drugmaker Mirum Pharmaceuticals said.

A cohort study lent support for a short course of prophylaxis in patients receiving non-liver solid organ transplants from donors with hepatitis C virus. (Lancet Gastroenterology & Hepatology)

Alcohol consumption in chronic hepatitis B patients was independently associated with increased risk for HCC, according to Chinese data. (Clinical Gastroenterology and Hepatology)

In a prospective study, a multi-target blood test showed better sensitivity versus ultrasound for detecting early-stage HCC, but didn’t match the specificity of ultrasound. (Journal of Hepatology)

Good news for patients with familial adenomatous polyposis (FAP): thanks to modern surveillance efforts, mortality in recent FAP cohorts matched that of the general population. (American Journal of Gastroenterology)

Medicaid expansion following the passage of the Affordable Care Act was associated with a 6.3% drop in the risk for death among colorectal cancer patients. (JAMA Network Open)

A nationwide Dutch study found that only 10% of patients diagnosed with Barrett’s-related dysplasia and cancer had previously undergone an endoscopy. (Gut)